CN119156218A - 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂 - Google Patents

用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂 Download PDF

Info

Publication number
CN119156218A
CN119156218A CN202380035206.5A CN202380035206A CN119156218A CN 119156218 A CN119156218 A CN 119156218A CN 202380035206 A CN202380035206 A CN 202380035206A CN 119156218 A CN119156218 A CN 119156218A
Authority
CN
China
Prior art keywords
pharmaceutical composition
istaroxime
individual
blood pressure
systolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380035206.5A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·西蒙森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wind Tree Therapy Co
Original Assignee
Wind Tree Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wind Tree Therapy Co filed Critical Wind Tree Therapy Co
Publication of CN119156218A publication Critical patent/CN119156218A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202380035206.5A 2022-04-20 2023-04-18 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂 Pending CN119156218A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332909P 2022-04-20 2022-04-20
US63/332,909 2022-04-20
PCT/US2023/018998 WO2023205183A1 (en) 2022-04-20 2023-04-18 Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock

Publications (1)

Publication Number Publication Date
CN119156218A true CN119156218A (zh) 2024-12-17

Family

ID=86331896

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380035206.5A Pending CN119156218A (zh) 2022-04-20 2023-04-18 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂

Country Status (9)

Country Link
EP (1) EP4511040A1 (https=)
JP (1) JP2025513337A (https=)
KR (1) KR20250005343A (https=)
CN (1) CN119156218A (https=)
AU (1) AU2023256547A1 (https=)
CA (1) CA3248625A1 (https=)
IL (1) IL316164A (https=)
MX (1) MX2024012948A (https=)
WO (1) WO2023205183A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025128432A1 (en) * 2023-12-11 2025-06-19 Windtree Therapeutics, Inc. Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1079807A (en) 1912-09-25 1913-11-25 Jonathan S Snyder Coat-closure.
NL95803C (https=) 1953-12-31 1900-01-01
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
US6063400A (en) 1997-07-02 2000-05-16 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
WO2006044986A1 (en) 2004-10-18 2006-04-27 Nitto Denko Corporation Intracellular peptide delivery
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
CN103315968B (zh) 2013-06-26 2015-04-01 中国生命药物治疗有限公司 一种注射用粉针剂及其制备方法
MX2021010483A (es) 2019-03-05 2021-10-01 Windtree Therapeutics Inc Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).

Also Published As

Publication number Publication date
JP2025513337A (ja) 2025-04-24
IL316164A (en) 2024-12-01
AU2023256547A1 (en) 2024-11-28
MX2024012948A (es) 2024-11-08
WO2023205183A1 (en) 2023-10-26
EP4511040A1 (en) 2025-02-26
CA3248625A1 (en) 2023-10-26
KR20250005343A (ko) 2025-01-09

Similar Documents

Publication Publication Date Title
Boorsma et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Lundwall et al. Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial
US20080032933A1 (en) Type V Phosphodiesterase Inhibitors and Natriuretic Polypeptides
US12343350B2 (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
JP2023025207A (ja) ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
EA022948B1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
Kitzman et al. A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: rationale and design of the Phase 2a HuMAIN trial
CN119156218A (zh) 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂
US20240293426A1 (en) Intravenous istaroxime for the treatment of acute heart failure
Doehner et al. Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study
US20220054540A1 (en) Ferric Carboxymaltose In The Treatment Of Heart Failure And In The Treatment Of Congestion In Heart Failure
JP2025513337A5 (https=)
Almeida et al. Three-vessel myocardial bridging: a possible cause of myocardial stunning
Sharma et al. Symptomatic myocardial bridges in children: a case report with review of literature
CA3130261C (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
US20070032557A1 (en) Method for administering levosimendan
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
Ohte et al. Impaired myocardial oxidative metabolism in the remote normal region in patients in the chronic phase of myocardial infarction and left ventricular remodeling
Boorsma Congestion and Compression in Cardiorenal Failure
US20080070917A1 (en) Methods for administering levosimendan
Sims et al. Acute Decompensated Heart Failure
WO2025233434A1 (en) Effect of intravenous ferric carboxymaltose on exercise capacity in symptomatic patients with heart failure and a preserved ejection fraction with iron deficiency with and without anaemia
WO2023070164A1 (en) Treatment of heart failure with preserved ejection fraction
CN116966176A (zh) 脂肪酸结合蛋白4抑制剂在治疗射血分数保留型心力衰竭中的应用
Weatherley et al. In Hospital Early (Within 5 Days) Worsening HF Predicts Adverse Outcome in Patients Admitted for AHF–Results from the Pre-RELAX-AHF Study

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination